CADTH Canadian Drug Expert Committee recommendation. Glecaprevir / Pibrentasvir (Maviret -- Abbvie Corporation) : indication : chronic hepatitis C virus infection.

CADTH Canadian Drug Expert Committee recommendation. indication : chronic hepatitis C virus infection. Glecaprevir / Pibrentasvir (Maviret -- Abbvie Corporation) :

Show other versions (3)

The CADTH Canadian Drug Expert Committee (CDEC) recommends that glecaprevir/pibrentasvir (GP) be reimbursed for the treatment of adult patients with HCV genotype 1, 2, 3, 4, 5, or 6 infection with or without compensated cirrhosis, including patients with HCV genotype 1 infection who were previously...

Full description

Saved in:
Bibliographic Details
Online Access: http://www.ncbi.nlm.nih.gov/books/NBK533338/
Full text
Corporate Author: CADTH Canadian Drug Expert Committee (Author)
Format: Electronic eBook
Language:English
Published: Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2018
Edition:Version 1.0.
Series:Common drug review clinical review report.
Subjects:
Hepatitis C, Chronic > drug therapy.
Quinoxalines > therapeutic use.
Sulfonamides > therapeutic use.
Antiviral Agents > economics.
Cost-Benefit Analysis.
Insurance, Health, Reimbursement.
Canada.

Internet

http://www.ncbi.nlm.nih.gov/books/NBK533338/
Full text

Similar Items